Options de traitement systémique, Centre de Preuves en Dermatologie

Guidelines atopic dermatitis Updated on Jul 25

Responsibility

The information provided by this website comes from sources deemed reliable. However, the Société Française de Dermatologie recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The Société Française de Dermatologie cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.

I have read and accept the general conditions of use of this website

Back to decision-making tree Print last updated on 08/02/2026

JAK Inhibitor

Baricitinib: in adult patients and children from 2 years of age

Baricitinib is a selective and reversible JAK1 and JAK2 inhibitor administered orally. Baricitinib has Marketing Authorization (MA) and is reimbursed in France for adults in the treatment of moderate-to-severe AD.

A European MA authorized baricitinib in October 2023 for children from 2 years of age with AD requiring systemic treatment.

This treatment is not reimbursed in France for children and adolescents at the time of writing these recommendations.

Recommended dose:

4 mg per day for adults or 2 mg per day for at-risk patientsor after achieving prolonged remission on 4 mg/day.

ANSM Recommendations (March 2023): JAK inhibitors should only be used in the absence of appropriate therapeutic alternatives in patients who are: aged 65 and over; smokers or long-term former smokers; presenting other cardiovascular risk factors or malignant tumors. Use with caution in patients with venous thromboembolic risk factors. Dosage recommendations are adjusted for certain groups of patients with risk factors.

The most common reported AEs for baricitinib: an increase in LDL cholesterol levels, upper respiratory tract infections, and headaches. Acneiform eruption is less frequent than with other JAK inhibitors. The frequency of HSV infections is higher in the 4 mg group compared to the 2 mg groups.

Concomitant use of emollients, TCS, and TCIs is possible.

➜ Upadacitinib

Back to decision-making tree Print

Was this article helpful to you?
Your opinion counts!

This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.